'Treatment disconnect' in kidney cancer: Rising mortality despite more small tumors, more surgerySeptember 20, 2006The rising incidence of kidney cancer may be due to an increase in the number of small, treatable kidney tumors, according to a study in the September 20 issue of the Journal of the National Cancer Institute. The incidence of a type of kidney cancer called renal cell carcinoma has been increasing over the past two decades. Despite the increased rates of surgery that have accompanied this trend, death rates have not decreased. Brent K. Hollenbeck, M.D., of the University of Michigan in Ann Arbor, and colleagues identified 34,503 cases of kidney cancer using data from nine Surveillance, Epidemiology, and End Results registries collected between 1983 and 2002. They observed that cancer incidence rose from 7.1 cases per 100,000 to 10.8 cases per 100,000. Tumors 4 cm or smaller, called small renal masses, accounted for the majority of this increase. Surgeries rose at the same rate, but mortality rates also increased. The authors suggest that surgery may not be an appropriate treatment for those tumors, which are often slow-growing and discovered in patients without symptoms related to kidney problems. "These data do not encourage an abrupt departure from the current treatment paradigm for kidney cancer; rather, they prompt reflection on our clinical practice and suggest the need for investigation to address the observed 'treatment disconnect' that we are treating more and more small renal masses but are not impacting mortality," they write. Journal of the National Cancer Institute |
|||||||||||||||||||||
| Related Kidney Cancer Current Events and Kidney Cancer News Articles New data: Hospital imaging centers poised to pull back, hitting patients hardest in rural areas Survivors and patients with cancers and heart disease, along with patient advocate organizations and physicians, today urged policymakers to enhance early diagnosis of deadly diseases by preserving access to advanced imaging, such as MRI and CT scans, in final health care reform legislation. Stem cell protein offers a new cancer target A protein abundant in embryonic stem cells is now shown to be important in cancer, and offers a possible new target for drug development, report researchers from the Stem Cell Program at Children's Hospital Boston. 2-drug combination appears safe and active in metastatic kidney cancer Fox Chase Cancer Center investigators report that a two-drug blockade of mTOR signaling appears safe in metastatic kidney cancer in a phase I trial. Finding Will Improve Accuracy of Cancer Diagnosis Van Andel Research Institute (VARI) investigators working in collaboration with Cleveland Clinic researchers have determined that two types of kidney tumors previously thought to be different diseases are actually variations of the same disease. Does a person's insurance coverage affect their access to quality cancer care? Does a person's insurance coverage affect their access to quality cancer care? According to researchers at Fox Chase Cancer Center, insurance coverage may not only affect a patient's access to health care, but also the quality of care they receive. Robotic assisted kidney cancer surgery proves to be beneficial to patients Fox Chase Cancer Center researchers find that outcomes of robotic assisted kidney cancer surgery, when performed by experienced surgeons at high volume centers, prove more beneficial to patients when compared to open surgery. Getting down to cancer basics Researchers have identified a new cancer gene - one that is common to many cancers and affects the most basic regulation of our genes. The new example - a gene on the X chromosome called UTX - is found in 10% of cases of multiple myeloma and 8% of esophageal cancers. Castrate resistant prostate cancer: New therapeutic approaches Today Dr. Martin Gleave of the Vancouver Prostate Centre in Canada gave a lecture about new approaches to treat castrate-resistant prostate cancer (CRCP) during the 24th Annual Congress of the European Association of Urology in Stockholm, Sweden. Freezing kidney cancer: Hot treatment should be new gold standard for destroying small tumors Freezing kidney tumors-using a safe minimally invasive interventional radiology treatment that kills the cancer 100 percent effectively without surgery-should be the gold standard or first treatment option for all individuals with tumors that are 4 centimeters in size or smaller. And, this treatment-interventional cryoablation-is a viable option for people with larger tumors, according to two studies presented at the Society of Interventional Radiology's 34th Annual Scientific Meeting. Roadkill study could speed detection of kidney cancer Large-scale data mining of gene networks in fruit flies has led researchers to a sensitive and specific diagnostic biomarker for human renal cell carcinoma, the most common type of kidney cancer. More Kidney Cancer Current Events and Kidney Cancer News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||